Immuneering Corporation
IMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $121,272 | $54,005 | $68,311 |
| - Cash | $227,563 | $26,355 | $35,866 | $36,145 |
| + Debt | $3,535 | $4,001 | $4,083 | $4,163 |
| Enterprise Value | – | $98,917 | $22,222 | $36,329 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$86 | $0 | $0 | -$175 |
| % Margin | – | – | – | – |
| EBITDA | -$14,879 | -$14,666 | -$15,392 | -$17,877 |
| % Margin | – | – | – | – |
| Net Income | -$14,965 | -$14,434 | -$15,046 | -$18,051 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.38 | -0.4 | -0.42 | -0.58 |
| % Growth | 5% | 4.8% | 27.6% | – |
| Operating Cash Flow | -$11,977 | -$9,446 | -$14,081 | -$14,511 |
| Capital Expenditures | -$7 | -$2 | -$9 | -$9 |
| Free Cash Flow | -$11,984 | -$9,448 | -$14,090 | -$14,520 |